Advanced Immune Monitoring with PepMix™ Peptide Pools!

Advanced Immune Monitoring with PepMix™ Peptide Pools!

Published on 24/09/2024

Precise immune monitoring to evaluate responses and changes of the immune system during and after therapy is critical in pre-clinical and clinical research and development. The selection of an appropriate and reliable antigen source has a crucial impact on the success of such studies.

Peptides are Better Antigens!

Peptides and pools mimic protein antigens or epitopes

Peptides can be synthesized with high purity, low bioburden and sterile

High batch-to-batch reproducibility

Precise quality control during production

No antigen expression required, avoiding bacterial contamination

ADCF policy

Work with JPT – The Peptide Expert - and take advantage of our unparalleled peptide quality & customer service. Our PepMix™ Peptide Pools have been used and validated in many immune monitoring studies. We have more than 500 PepMix™ Peptide Pools in stock:

PepMix™ for TAAs

PepMix™ for Infectious Disease Antigens

PepMix™ for other antigens

Custom PepMix™

Case Studies using PepMix™

1. Vaccine Development: In recent years, PepMix™ has been pivotal in several high-profile vaccine development projects. Several of the COVID vaccines have been developed with SARS-CoV2 PepMixes ™ and our control pool CEFX as stimulating agent during immune monitoring. With PepMix™ you are able to measure immune responses effectively, providing critical data about vaccine efficacy.

Selected Publications:

Repeated COVID-19 Vaccination Drives Memory T- and B-cell Responses in Kidney Transplant Recipients: Results From a Multicenter Randomized Controlled TrialMalahe et al., Transplantation (2024) - PMID: 38902860

A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2 Koseki et al., Vaccines (2023) - PMID: 38140172

Immunogenicity and safety of a two-dose regimen with hepatitis E virus vaccine in healthy adults in rural Bangladesh: A randomized, double-blind, controlled, phase 2/pilot trial Øverbø et al., Vaccine (2023) - PMID: 36599736

Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trialPannus et al., Plos Global Public Health (2022) - PMID: 36962838

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans Sahin et al., Nature (2021) – PMID: 34044428

A SARS-CoV-2 mRNA Vaccine — Preliminary ReportJackson et al., N Engl J Med. (2020) – PMID: 32663912

BNT162b Vaccines Protect Rhesus Macaques From SARS-CoV-2Vogel et al., Nature (2021) – PMID: 33524990

Evaluation of the mRNA-1273 Vaccine Against SARS-CoV-2 in Nonhuman PrimatesCorbett et al., N Engl J Med. (2020) – PMID: 32722908

Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques Mercado et al., Nature (2020) – PMID: 32731257

A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidateSanchez-Felipe et al., Nature (2021) – PMID: 33260195

SARS-CoV-2 Spike Glycoprotein Vaccine Candidate NVX-CoV2373 Immunogenicity in Baboons and Protection in MiceTian et al., Nature Communications (2021) – PMID: 33446655

Application Note: “Cross-reactive T cells enhance immune responses in SARS-CoV-2 infection and vaccination” by Lucie Loyal & Andreas Thiel (Charité Berlin)

2. Disease Diagnostics: PepMix™ has also played a crucial role in disease diagnostics. Our peptide pools are often used to monitor the immune response of patients undergoing treatment. This application highlights not only the diagnostic potential of PepMix™ but also its capability to track the progression and treatment response of infectious diseases accurately. To get specific and accurate information of a disease, the use of synthetic peptides in diagnostics have increased in the last few decades, because of their high purity profile and ability to get modified chemically.

CD3-downregulation identifies T-helper-cells with superior functionality and distinct metabolism in SARS-CoV2-vaccination- and recall-antigen-specific immunitySattler et al., JCI Insight (2024) – PMID: 38206757

Identification of a spike-specific CD8+ T cell epitope following vaccination against the Middle East respiratory syndrome coronavirus in humans Harrer et al., Journal of Infectious Diseases (2024) – PMID: 38195212

Enhanced detection of antigen-specific T cells by a multiplexed AIM assayLemieux et al., Cell Rep Methods (2024) – PMID: 38228152

T Cell Responses against Orthopoxviruses in HIV-Positive Patients Stefanie et al., Vaccines (2024) – PMID: 38400115

Functional Immune Monitoring of BK Virus And Donor‐Specific T‐cell Effector Immune Responses to Guide Treatment Decision‐Making After Kidney Transplantation; an Illustrative Case Report And Literature Review Lepore et.al., Transplant Infectious Disease (2020) – PMID: 33070461

Cytomegalovirus (CMV) Immune Monitoring with ELISPOT and QuantiFERON-CMV Assay in Seropositive Kidney Transplant Recipients Lee et al., Plos One (2017) – PMID: 29232714

Immune Monitoring to Predict and Prevent Infection Palmer et al., US Patent 20,160,377,602, 2016

Application Note: “Developing Multi-HIV Antigen Specific T cells as a Component of a Cure Strategy” by S. Lam, C. R. Cruz and C. Bollard (Center for Cancer and Immunology Research, Washington DC)

3. Immune Toxicity of Biologics: An understanding of the immune toxicity of biologics or unwanted immunogenicity is essential for safe therapeutic development, especially when using viral vectors or CRISPR/Cas9. PepMix™ is utilized to assess unwanted immune responses in patients treated with gene therapy. The studies underscored the importance of immune monitoring in predicting and managing potential adverse effects, ensuring patient safety and treatment efficacy.

LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 studyMusher et al., The Lancet Oncology (2024) – PMID: 38547893

Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trialWang et al., Signal Transductions and Targeted Therapy (2024) – PMID: 38653979

Durable immunogenicity, adaptation to emerging variants and low dose efficacy of AAV-based COVID19 platform in macaques Zabaleta et al., Molecular Therapy (2022) – PMID: 35546782

Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trialCasazza et al., Nature Medicine (2022) – PMID: 35411076

Gene Transfer in Adeno-Associated Virus Seropositive Rhesus Macaques Following Rapamycin Treatment and Subcutaneous Delivery of AAV6, but Not Retargeted AAV6 VectorsStone et al., Human Gene Therapy (2021) – PMID: 32998579

Go to our website for more PepMix™ references!

ISO Plus Quality Grade for GLP Compliance

We are proud to offer our ISO Plus quality grade, designed to meet Good Laboratory Practice (GLP) compliance. This includes the use of dedicated equipment and consumables, as well as updated Certificates of Analysis (CoA) and Material Safety Data Sheets (MSDS) with cytotoxicity information. These enhancements ensure that our products not only meet but exceed the stringent requirements of GLP, providing you with reliable and reproducible results for your critical studies.

Learn More

For detailed illustrations, references, and protocols on how PepMix™ can enhance your research, please visit our website. Our comprehensive resources provide in-depth information on the application and benefits of our peptide pools, ensuring you have all the tools you need to succeed in your immune monitoring endeavors.

Contact Us

Our team of experts is always here to support your research needs. Contact us today to learn how PepMix™ can advance your immune monitoring projects.